About OrsoBio
OrsoBio is a company based in Palo Alto (United States) founded in 2021.. OrsoBio has raised $153.33 million across 4 funding rounds from investors including Lilly, HHS and Enavate Sciences. OrsoBio offers products and services including ACC2 inhibitor (TLC-3595), LXR inverse agonist (TLC-2716), Mitochondrial protonophore (TLC-6740), Mitochondrial protonophore (TLC-1180), and Mitochondrial protonophore (TLC-1235). OrsoBio operates in a competitive market with competitors including Sana Biotechnology, Semma Therapeutics, Adocia, Ardelyx and Rezolute, among others.
- Headquarter Palo Alto, United States
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Orsobio, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$153.33 M (USD)
in 4 rounds
-
Latest Funding Round
$1.7 M (USD), Series B
Feb 25, 2025
-
Investors
Lilly
& 7 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OrsoBio
OrsoBio offers a comprehensive portfolio of products and services, including ACC2 inhibitor (TLC-3595), LXR inverse agonist (TLC-2716), Mitochondrial protonophore (TLC-6740), Mitochondrial protonophore (TLC-1180), and Mitochondrial protonophore (TLC-1235). The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhibits ACC2 to enhance insulin sensitivity for type 2 diabetes patients.
Targets LXR to reduce triglycerides and cholesterol in dyslipidemias.
Increases energy expenditure for metabolic health in lipodystrophies.
Boosts metabolism to address obesity and related conditions.
Improves cardiovascular health in metabolic disorders.
Augments NAD+ for better mitochondrial function in organ failure.
Unlock access to complete
Product Management Team
4 people
Leadership Team
4 people
Finance and Accounting
1 people
Senior Team
1 people
Unlock access to complete
Funding Insights of OrsoBio
OrsoBio has successfully raised a total of $153.33M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $1.7 million completed in February 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series B — $1.7M
-
First Round
First Round
(22 Sep 2022)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2025 | Amount | Series B - OrsoBio | Valuation |
investors |
|
| Aug, 2024 | Amount | Series B - OrsoBio | Valuation | Ascenta Capital | |
| Oct, 2023 | Amount | Series A - OrsoBio | Valuation | Longitude Capital , Enavate Sciences |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in OrsoBio
OrsoBio has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, HHS and Enavate Sciences. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Ascenta Capital is focused on biopharma investment and growth.
|
Founded Year | Domain | Location | |
|
Venture capital funding is provided by Samsara BioCapital in California.
|
Founded Year | Domain | Location | |
|
Private equity firm focused on life science sector
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by OrsoBio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - OrsoBio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Orsobio Comparisons
Competitors of OrsoBio
OrsoBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, Semma Therapeutics, Adocia, Ardelyx and Rezolute, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
|
|
| domain | founded_year | HQ Location |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for metabolic and orphan diseases are developed by Rezolute.
|
|
| domain | founded_year | HQ Location |
Developer of autologous cell therapies
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Orsobio
Frequently Asked Questions about OrsoBio
When was OrsoBio founded?
OrsoBio was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Where is OrsoBio located?
OrsoBio is headquartered in Palo Alto, United States. It is registered at Palo Alto, California, United States.
Is OrsoBio a funded company?
OrsoBio is a funded company, having raised a total of $153.33M across 4 funding rounds to date. The company's 1st funding round was a Series A of $84.63M, raised on Sep 22, 2022.
What does OrsoBio do?
OrsoBio was founded in 2021 and is based in Palo Alto, United States. Focus is placed on the biotechnology sector, where therapeutics targeting core energy metabolism pathways are developed for conditions including type-2 diabetes, severe dyslipidemias, and lipodystrophies. Drug candidates such as the ACC2 inhibitor TLC-3595, LXR inverse agonist TLC-2716, mitochondrial protonophore TLC-6740, and TLC-1235 are advanced through research and development operations.
Who are the top competitors of OrsoBio?
OrsoBio's top competitors include Sana Biotechnology, Semma Therapeutics and Adocia.
What products or services does OrsoBio offer?
OrsoBio offers ACC2 inhibitor (TLC-3595), LXR inverse agonist (TLC-2716), Mitochondrial protonophore (TLC-6740), Mitochondrial protonophore (TLC-1180), and 2 more products and services.
Who are OrsoBio's investors?
OrsoBio has 8 investors. Key investors include Lilly, HHS, Enavate Sciences, Ascenta Capital, and Woodline Partners.